Background. Breast cancer-related lymphedema (BCRL) is a significant complication for women undergoing treatment. We assessed BCRL incidence and risk factors in a large population-based cohort. Methods. We utilized the Olmsted County Rochester Epidemiology Project Breast Cancer Cohort from 1990-2010 and ascertained BCRL and risk factors. The cumulative incidence estimator was used to estimate the rate of BCRL; competing risks regression was used for multivariable analysis. Results. A total of 1794 patients with stage 0-3 breast cancer with a median of 10 years follow-up were included. The cumulative incidence of BCRL diagnosis within 5 years was 9.1% [95% confidence interval (CI) 7.8-10.5%]. No BCRL events occurred among patients without axillary surgery. In the axillary surgery subset (n = 1512), the 5-year incidence of BCRL was 5.3% in sentinel lymph node (SLN) surgery and 15.9% in axillary dissection (ALND) patients (p \ 0.001). In patients treated with surgery only, BCRL rates were not different between ALND versus SLN (3.5 and 4.1% at 5 years, p = 0.36). Addition of breast or chest wall radiation more than doubled the BCRL rate in ALND patients (3.5 vs. 9.5% at 5 years, p = 0.01). The groups with highest risk ([25% at 5 years) all involved ALND with nodal RT and/or anthracycline/cytoxan ? taxane chemotherapy. In multivariable analysis of patients with any axillary surgery factors significantly associated with BCRL were ALND, chemotherapy, radiation, and obesity. Conclusions. BCRL is a sequelae of multimodal breast cancer treatment and risk is multifactorial. BCRL rates are higher in patients receiving chemotherapy, radiation, ALND, more advanced disease stage, and higher body mass index.
Breast cancer-related lymphedema (BCRL) is a wellknown complication and the most common morbidity resulting from breast cancer treatments. The incidence of lymphedema ranges from 3-65% depending on the treatment, mode of lymphedema diagnosis, and length of follow-up. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Survivors may experience a substantial degree of functional impairment, psychological morbidity, and diminished quality of life. [16] [17] [18] [19] Lymphedema occurs when protein-rich fluid accumulates in soft tissues because of interruption of lymphatic flow. 20 As a result, factors that influence this disruption have been implicated in the development of lymphedema. Additionally, data indicates that 75% of BCRL cases occur within the first year after surgery and 90% within 3 years, among patients undergoing prospective monitoring. 21 Numerous studies have shown that more extensive axillary surgery with axillary lymph node dissection (ALND) significantly increase the risk for development of BCRL compared with sentinel lymph node (SLN) surgery. 22 Additionally, regional nodal irradiation (RNI), which involves radiation targeting the axilla, also has been associated with increased rates of BCRL. 1 However, other treatment and patient-related factors have not been as strongly linked to BCRL. Knowledge of the incidence of BCRL related to patient and treatment factors is important for patient education. Furthermore, improved recognition of patients at higher risk for BCRL should facilitate early risk-reduction strategies with proactive surveillance and treatment, which has been shown to improve patient outcomes and quality of life. 23 In this population-based study, we aimed to determine the incidence of BCRL in a large cohort of patients diagnosed with breast cancer with long-term follow-up and to estimate the association of demographic and clinical characteristics with BCRL.
METHODS
We utilized the Olmsted County Rochester Epidemiology Project Breast Cancer Cohort, a population-based sample of all incident breast cancer cases diagnosed in Olmsted County, MN residents in 1990-2010. Trained nurse abstractors performed a comprehensive search of medical records and noted occurrences of the key words: ''edema''; ''heaviness''; ''lymphedema''; ''puffiness''; and ''swelling'' affecting the upper extremities. All available clinical notes were examined, including those from surgery, oncology, primary care, physical therapy, and lymphedema clinic providers. All cases with definite or probable lymphedema were included as BCRL.
Time to BCRL was calculated from date of definitive breast surgery to date of diagnosis of BCRL. Patients in the cohort underwent a range of surgical and adjuvant treatments, which allow the relationship of each treatment modality and BCRL to be assessed. Data on other events during follow-up, including dates of recurrence (local and systemic), diagnosis of new contralateral primary breast cancer, last follow-up, and death also were collected. Patient, clinicopathologic, and treatment variables collected included age, type of breast and axillary surgery, radiation fields, type(s) of chemotherapy, pathologic stage, and baseline BMI. Breast surgery was classified as breast-conserving surgery (BCS), unilateral mastectomy, or bilateral mastectomy; bilateral mastectomy may have been performed for either bilateral cancer or for unilateral cancer with contralateral prophylactic mastectomy. In patients with synchronous bilateral cancer at baseline, data from the highest stage side with the most extensive treatment was used for analysis. Axillary surgery was classified as the most extensive surgery, so patients who underwent SLN surgery and ALND were classified as ALND.
Statistical Analysis
Time-to-event methods were used to analyze the outcome of definite/probable BCRL with time calculated as the years from the date of definitive cancer surgery to the earliest of the following events: BCRL diagnosis, recurrence, new contralateral primary, last follow-up, or death. The cumulative incidence estimator was used to estimate the proportion with BCRL diagnosis while accounting for the competing risks of death, recurrence, or new contralateral primary. Patients not experiencing any of these events were censored at last follow-up. Fine and Grey competing risks regression was used for multivariable analysis assessing risk factors for BCRL, which are reported with hazard ratios (HRs) and 95% confidence intervals (CIs). Analysis was performed using SAS (Version 9.4, SAS Institute Inc., Cary, NC) and the cmprsk package for R software.
24 p values \0.05 were considered statistically significant.
RESULTS
A total of 1794 patients with stage 0-3 breast cancer with a median of 10 years follow-up were included. Breast cancer was unilateral in 1764 (98%) and bilateral in 30 (2%). Cohort characteristics are summarized in Table 1 . Median age at cancer diagnosis was 60 years, and 44% were overweight or obese at baseline. Stage distribution was 17% stage 0, 47% stage I, 28% stage II, and 7% stage III. A majority (58%) underwent BCS, whereas 28% underwent unilateral mastectomy and 13% bilateral mastectomy. Most patients underwent axillary staging surgery, with 44% undergoing ALND, 40% SLN surgery only, and 16% having no axillary surgery. The median number of lymph nodes examined was 3 for SLN surgery and 16 in ALND. Overall, 57% received radiation and 29% received chemotherapy.
Incidence of BCRL
A total of 209 BCRL events were observed during follow-up; the majority (78%, 162/209) occurred within 5 years of breast cancer surgery. The cumulative incidence of BCRL diagnosis was 6.9% (95% CI 5.8-8.2%) at 2 years, 9.1% (95% CI 7.8-10.5%) at 5 years, and 11.4% (95% 10.0-13.0%) at 10 years. No BCRL events were observed among the 282 patients who did not undergo axillary surgery, who had a median of 10.6 years of followup. Restricted to the subset with axillary surgery (n = 1512), the 2-, 5-, and 10-year rates of BCRL were 8.2% (95% CI 6.9-9.7%), 10.8% (95% CI 9.3-12.5%), and 13.5% (95% CI 11.8-15.3%), respectively. Subsequent analyses of characteristics associated with BCRL were restricted to the axillary surgery subset.
Impact of Patient Factors
Rates of BCRL were higher in patients with BMI C25 versus \25 (14.3 vs. 8.0% at 5 years, p = 0.002). Overweight (BMI 25-29.99) and class I obesity (BMI 30-34.99) had similar rates (14.4 and 13.0% at 5 years), whereas morbidly obese (BMI C 35) had a slightly higher rate at 17.1% (Table 2 ). Pathologic stage also was significantly associated with BCRL in univariate analysis (p \ 0.001), with similar 5-year cumulative incidence for stage 0 (4.2%) and stage I (5.4%) but more than double that for stage II (14.1%) and the highest rate in stage III (37.8%).
Impact of Type of Surgery
Overall, mastectomy versus lumpectomy was not associated with higher rates of BCRL (p = 0.42). The 5-year incidence of BCRL was 5.3% (95% CI 3.8-7.1%) in SLN surgery and 15.9% (95% CI 13.5-18.6%) in ALND patients (p \ 0.001). Figure 1 shows cumulative incidence curves for combinations of breast and axillary surgery. In patients treated with surgery only (no radiation and no chemotherapy), BCRL rates were not different between ALND versus SLN surgery (3.5 and 4.1% at 5 years, p = 0.36).
Impact of Radiation Therapy and Chemotherapy
In patients without chemotherapy, addition of breast or chest wall radiation to SLN surgery did not increase BCRL substantially (4.8 vs. 4.1% at 5 years, p = 0.79) but did more than double the rate in ALND patients (9.5 vs. 3.5% at 5 years, p = 0.01). Nodal radiation following ALND resulted in a marked increase in BCRL incidence to 26.9% at 5 years (Table 2 ; Fig. 2 ). Because only a small number of SLN surgery patients received nodal radiation, we were unable to estimate the effect of nodal radiation in this subset. Chemotherapy, including taxane and to a lesser degree anthracycline, also increased the incidence of BCRL in ALND patients. Addition of anthracycline chemotherapy (without RT) increased the 5-year incidence of BCRL from 3.5% (ALND surgery only) to 8.4% (ALND and AC without taxane chemotherapy; p = 0.1), whereas ALND and AC ? T chemotherapy had a much higher 5-year incidence of 33.6% (p \ 0.001). The highest 5-year rates of BCRL were seen in patients treated with ALND plus nodal RT (26.9%), ALND plus nodal RT and AC chemotherapy (29.3%), ALND and AC ? T chemotherapy (33.6%), ALND plus breast or chest wall only RT and AC ? T chemotherapy (33.9%), and ALND with nodal RT and AC ? T chemotherapy (39.7%; Table 2 ; Fig. 2 ).
Multivariable Analysis
In multivariable analysis among patients with axillary surgery (Table 3) 
DISCUSSION
Our study showed that the risk for developing BCRL is multifactorial and not solely related to the extent of axillary surgery. Factors that influenced BCRL rates included the delivery of chemotherapy, use of radiation, ALND, more advanced stage of disease, and higher BMI.
More extensive axillary surgery was associated with higher rates of BCRL as patients who had ALND had a 15.9% rate of incidence of BCRL over 5 years compared with 5.3% with SLN surgery. However, further analysis and examining all treatment modalities, the rate of BCRL was not different comparing patients who had SLN surgery or ALND only without chemotherapy or radiation, indicating that surgery alone is not the key driver for BCRL. Adjuvant radiation had a higher risk of lymphedema in patients undergoing ALND but not SLN surgery. Axillary nodal radiation was associated with an increased incidence of BCRL compared with breast or chest wall radiation alone. Patients with higher BMI also had a higher incidence of BCRL. Perhaps most interestingly, our findings showed that chemotherapy, specifically the use of taxanes, contributed to the highest rates of BCRL. Correspondingly, patients with more advanced-stage disease had higher rates of lymphedema in univariate analysis; however, after adjusting for treatment variables in multivariable analysis, stage was not an independent predictor of BCRL, suggesting that higher rates in more advanced stages are likely a result of more aggressive therapies.
The true incidence of BCRL is difficult to measure, because the symptoms can have a delayed and variable onset and the criteria used to diagnose lymphedema are not standardized, as both subjective and objective measures are utilized. 25 Reported rates of lymphedema are disproportionate, ranging from less than 5% with lumpectomy alone to more than 60% when mastectomy, ALND, and axillary radiation are combined. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Historically, ALND was the a Only common treatment combinations with sufficient numbers of patients for estimation were included in this table primary operation to stage the axilla in all patients presenting with breast cancer. During the past two decades, SLN surgery has replaced ALND as the staging procedure in clinically node-negative patients and has led to a decrease in lymphedema. The landmark National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial randomized 5,611 clinically node-negative patients to SLN surgery followed by mandatory ALND versus SLN surgery proceeding to ALND only if any of the SLNs were positive for metastatic disease. 26 Morbidity results from this study showed that BCRL rates were 14% in the ALND group versus 8% in the SLN group at 36 months of follow-up. 2 Another study with 10 years of follow-up of 265 patients reported lymphedema rate of 34.8% in ALND patients and 4.6% in SLN surgery patients. 3 Omission of ALND in these studies is associated with much lower rates of lymphedema. In our cohort, patients who underwent ALND had increased BCRL compared with SLN surgery (HR 2.69, p \ 0.001). However, in the surgery-only patients (without radiation or chemotherapy), rates of BRCL were similar.
The association between axillary nodal irradiation and lymphedema is well documented in the literature. In a review by Erickson et al., lymphedema was reported in 41% of patients who underwent axillary irradiation therapy in addition to surgery as opposed to 17% of patients treated with surgery only. 7 A retrospective study of 727 patients showed that the only significant risk factor for lymphedema was the addition of regional nodal irradiation (RNI). 9 With a median follow-up of 72 months, the 10-year risk of developing lymphedema was 1.8% for breast radiation alone versus 8.9% for RNI, and the extent of axillary dissection was not predictive for lymphedema. Additionally, the recently published MA.20 trial of 1,832 women randomized to whole breast radiation with RNI versus whole breast radiation alone found that patients who had RNI had a significantly higher incidence of lymphedema (8.4 vs. 4.5%, p = 0.001). 27 . Previous studies have shown that chemotherapy contributes to BCRL, [28] [29] [30] [31] but other studies have not shown this correlation. 32 In a recent retrospective analysis of 273 patients who all underwent ALND, 74 (27.1%) developed BCRL over a mean follow-up period of 2.67 years. 33 They found that patients who had taxane-based chemotherapy were nearly three times more likely to have BCRL compared with patients who did not receive chemotherapy at all. Previous studies have suggested potential mechanisms of action whereby repeated taxane exposure induced endothelial inflammation leading to abnormal capillary permeability. 34, 35 These studies showed development of edema in patients receiving taxanes using capillaroscopy and capillary filtration tests involving 99m Tc-labelled albumin. They concluded that taxanes caused an abnormality in capillary permeability and also progressive accumulation of proteins in the interstitial space. Future studies are needed to confirm that taxanes lead to higher risks of lymphedema compared with other chemotherapeutic agents.
Our study showed that patients who received taxanebased chemotherapy had the highest rates of BCRL and significantly higher than nontaxane-based regimens. Chemotherapy has been underappreciated as a risk factor for lymphedema. Recognition that this can be a significant and independent contributor of BCRL can lead to greater informed risk-benefit discussions with patients when consideration of chemotherapy is needed.
Patients with more advanced disease typically receive more aggressive locoregional and systemic therapies. In our study, advanced stage was associated with higher rates of BCRL; however, this was not significant on multivariable analysis, indicating that the higher risk with advanced stage is linked to the greater extent of axillary surgery and use of radiation and systemic treatments. These findings are in keeping with a previous report of 455 patients with median follow-up of 53 months, which showed that the incidence of lymphedema in patients with stages I-II breast cancer was lower than in patients with stage III (24 and 35.3%, respectively, p = 0.018). 36 Higher body mass index (BMI) is known to be associated with higher BCRL risk, and our study findings showed that obesity was associated with higher rates of BCRL. NSABP B-04, which randomized 1665 patients to radical mastectomy, total mastectomy with radiation, and total mastectomy alone, showed that increasing BMI had a significant correlation with increasing incidence of lymphedema. 4 Multiple studies have correlated obesity to be an independent risk factor for development of BCRL. [36] [37] [38] ALND, nodal radiation, and chemotherapy are treatment-related contributors to lymphedema, and obesity is a patient-related factor. Recognition that certain patients are more prone to develop lymphedema can allow individualized survivorship plans and lead to earlier detection and treatment, which leads to improved outcomes and better overall quality of life. 23, [39] [40] [41] [42] Limitations of the current study include its retrospective nature and method of determination of lymphedema. Diagnosis of BCRL in our cohort was made by chart review, which is less reliable compared with a uniform objective measurement in a prospective cohort of patients. To ensure the most comprehensive assessment for lymphedema, trained nurse abstractors were used for review of clinical notes across all specialities to assess for the development of lymphedema; however, we acknowledge that lack of arm measurements and prospective study is a significant limitation. In addition, breast cancer treatment is multimodal in nature and many patients with BCRL undergo a combination of therapies. Determining which treatment has the greatest impact to the development of BCRL can be challenging.
BCRL is a significant morbidity affecting many breast cancer survivors, resulting in a reduced quality of life. Extent of axillary surgery has long been implicated as the dominant factor causing lymphedema and locoregional therapy as the sole etiology. However, BCRL risk is a consequence of multimodal breast cancer treatment and is associated with axillary surgery, axillary radiation, and chemotherapy with the highest risk occurring in patients with advanced disease requiring all treatment modalities. Higher BMI is an independent patient-related factor associated with increased risk for developing BCRL.
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